Long-term hydronidone for liver scarring in hepatitis B
Treatments studied
Part of Digestive system clinical trials.
This trial tests a long-term treatment called hydronidone for liver scarring (fibrosis) caused by chronic hepatitis B. It aims to see if the treatment can help slow or reverse liver damage in people who are already on antiviral therapy or starting treatment for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had chronic hepatitis B (positive for hepatitis B surface antigen) for at least 6 months.
- You either have never taken antivirals for hepatitis B (with certain liver stiffness scores) OR you have been on a stable antiviral like tenofovir or entecavir for at least 6 months (with a liver stiffness score above 9.0).
- Your liver enzyme (ALT) level is less than 8 times the upper limit of normal.
- You have not taken certain Chinese herbal anti-scarring medicines in the last 3 months.
- You agree to use effective birth control during the study and for 6 months after, and are not pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
This trial tests a new medicine called Hydronidone Capsule in healthy people to see how the body processes it and whether it is safe. If you are in good health, you may be able to join this first-in-human study.
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.